YN340288 EGFR Protein Tyrosine K... 945830-38-6

EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.

YN340034 CUDC-101 1012054-59-9

CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.

YN340244 Erlotinib D6 1034651-23-4

Erlotinib D6 (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2nM for human EGFR.

YN340132 Allitinib tosylate 1050500-29-2

AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family ...

YN340182 Poziotinib 1092364-38-9

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.

YN340128 Dacomitinib 1110813-31-4

Dacomitinib (PF299804, PF299) is a potent, irreversible pan-ErbB inhibitor, mostly to EGFR with IC50 of 6 nM in a cell-free assay, effective against NSCLCs with EGFR or ERBB2 mutations (resistant to gefitinib) as ...

YN340093 Erlotinib D6 hydrochloride 1189953-78-3

Erlotinib D6 hydrochloride (CP-358774 D6 hydrochloride) a deuterium labeled Erlotinib Hydrochloride. Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC50 of 2nM.

YN340164 Icotinib Hydrochloride 1204313-51-8

Icotinib Hydrochloride (BPI-2009) is a potent and specificEGFRinhibitor with an IC50 of 5nM; also inhibits mutant EGFRL858R, EGFRL858R/T790M, EGFRT790M and EGFRL861Q.

YN340096 WZ4002 1213269-23-8

WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM in BaF3 cell line does not inhibit ERBB2 phosphorylation (T798I).

YN340090 WZ-3146 1214265-56-1

WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM does not inhibit ERBB2 phosphorylation (T798I).

YN340051 Pyrotinib Racemate 1246089-97-3

Pyrotinib Racemate is the racemate of Pyrotinib. Pyrotinib is a potent and selective EGFR/HER2 dual inhibitor.

YN340050 Pyrotinib 1269662-73-8

Pyrotinib (SHR-1258) is a potent and selectiveEGFR/HER2dual inhibitor with IC50s of 13 and 38nM, respectively.

YN340223 Olmutinib 1353550-13-6

Olmutinib is a novel third-generation epidermal growth factor receptor (EGFR) mutation-specific tyrosine kinase inhibitor (TKI). Also a potent inhibitor of Bruton's tyrosine kinase.

YN340053 Theliatinib 1353644-70-8

Theliatinib (HMPL-309) is a potent, ATP-competitive, orally active and highly selectiveEGFRinhibitor with a Ki of 0.05nM and an IC50 of 3nM. Theliatinib has an IC50 of 22nM forEGFR T790M/L858R mutant. Theli...

YN340180 Rociletinib 1374640-70-6

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT in cell-free assays, respectively. Phase 2.

YN340152 CNX-2006 1375465-09-0

CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.

YN340052 Pyrotinib dimaleate 1397922-61-0

Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selectiveEGFR/HER2dual inhibitor with IC50s of 13 and 38nM, respectively.

YN340131 Afatinib impurity 11 1402086-20-7

Afatinib impurity 11 is an impurity of Afatinib. Afatinib is an irreversibleEGFRfamily inhibitor with IC50s of 0.5nM, 0.4nM, 10nM and 14nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.

YN340247 Mutated EGFR-IN-1 1421372-66-8

Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutatedEGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant. More information can be fo...

YN340155 Mutant EGFR inhibitor 1421373-62-7

Mutant EGFR inhibitor is a potent and selective mutantEGFRinhibitor extracted from patent WO 2013014448 A1; inhibits EGFRL858R, EGFRExon 19 deletion and EGFRT790M.